Pick two or more compounds to see, area by area, which of them have a reported concern in studies: testosterone suppression, cholesterol and blood fats, liver, blood sugar and cancer in rodent studies. Each finding keeps its direction and its evidence type. It shows research findings, not advice to combine anything.
| Area | SR9009 | Cardarine | Concern reported for more than one? |
|---|---|---|---|
| Testosterone suppression | Not measured | Not measured | — |
| Cholesterol and blood fats | No human data | Reported change, not counted as a concern: | — |
| Liver | Concern reported | Concern reported
Reported change, not counted as a concern:
| Yes, 2 of 2 |
| Blood sugar (glucose/insulin) | No human data | Reported change, not counted as a concern:
| — |
| Cancer in rodent studies | None found in our records | Concern reported | — |
Areas where more than one compound has a reported concern
- Liver: SR9009 and Cardarine each have a reported concern in this area.
A shared area means both (or all) compounds have a reported concern there, from separate studies of each one. It is not a measured interaction, and it does not show that the risks add up or by how much. Animal findings and case reports keep their labels; they are not trial results in people.
Bloodwork the studies tracked
ALT/AST (liver enzymes), Bilirubin, INR (blood clotting), Lipid panel (HDL, LDL, triglycerides), Fasting glucose and insulin, CK (creatine kinase)
A summary of published research, not medical advice. It shows what studies found and does not tell anyone how to use these compounds.
What the checker looks at
| Area | What counts as a reported concern |
|---|---|
| Testosterone suppression | The compound’s suppression score (mild, moderate or marked) from the cited studies, marked “human data” or “animal data”. “Not measured” means there are no data. |
| Cholesterol and blood fats | An adverse change in the compound’s record, such as lower HDL or raised cholesterol. Changes that were improvements in trials (for example higher HDL and lower triglycerides with cardarine) are shown as “reported change, not counted as a concern”. |
| Liver | Raised liver enzymes or bilirubin, or liver injury, in people (trials or case reports) or in animal studies, each with its label. |
| Blood sugar | Higher glucose, insulin or HbA1c, lower insulin sensitivity, or low blood sugar. Lower fasting insulin in a trial counts as a change, not a concern. |
| Cancer in rodent studies | Tumors in long-term rat or mouse studies, kept apart from liver findings in people. Cardarine’s development stopped over these findings. |
The last column shows whether more than one of your compounds has a reported concern in the same area. That means each has a concern there from separate studies of that compound. It is not a measured interaction, and it does not show that the risks add up or by how much. “None found in our records” means the studies we hold did not report one; “No human data” means the compound has not been studied in people. Each finding keeps its evidence label, so a single case report or an animal study is not shown as if it were a trial result. Below the table, the checker lists the blood markers the studies tracked.
What no checker can tell you
The checker adds up findings from separate studies of single compounds. We found no controlled human trial of any SARM stack. What exists are case reports, and they are worrying:
- A 25-year-old man took LGD-4033 (10 mg) with MK-677 (15 mg) daily for 5 weeks. Total testosterone fell 62% and free testosterone 86%, HDL fell 36%, LDL rose 40% and the liver enzyme ALT rose 205% (Cardaci 2022).
- A 43-year-old man who used ostarine with cardarine developed liver injury (ALT up to 922 U/L) and severe muscle breakdown (CPK up to 86,435 U/L); he recovered over about 6 weeks (Kintz 2021).
- A 47-year-old bodybuilder who used RAD-140, andarine and MK-677 for 3 months developed blood sugar of 558 mg/dL and needed insulin (Sotorník 2022).
- A young active-duty Marine developed cholestatic liver injury with jaundice after about 3 months of LGD-4033, RAD-140 and YK-11 (Lee 2023).
- Stacking is common: in Swedish healthcare urine samples that tested positive for SARMs, more than half contained two or more (Bohlin 2024).
- A product may hold more than its label says: in a 2017 analysis, 25% of products sold as SARMs contained substances not listed on the label (Van Wagoner 2017).
The checker does not model drug interactions, your health, your dose or how long you would take anything. A doctor and blood tests can; a table cannot.
Written guides on common stacks
- RAD-140 and cardarine
- LGD-4033 and MK-677
- MK-677 and RAD-140
- YK-11 stacks
- Ostarine stacks
- RAD-140 stacks
- Cutting stacks
Related tools and guides
- PCT planner: when each compound is cleared and the PCT drugs that were studied.
- Compare: two compounds side by side.
- SARMs side effects: every reported side effect by body system, with evidence levels.
- SARMs database: all compounds in one table.